<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/' xmlns:blogger='http://schemas.google.com/blogger/2008' xmlns:georss='http://www.georss.org/georss' xmlns:gd="http://schemas.google.com/g/2005" xmlns:thr='http://purl.org/syndication/thread/1.0'><id>tag:blogger.com,1999:blog-7692026254079067189</id><updated>2024-12-18T19:25:37.779-08:00</updated><title type='text'>medicamomentosa</title><subtitle type='html'>This is a blog that mainly consists of health and public health related articles, research findings from highly recognized journal, journal link, analysis and news update and blogger&#39;s experience with patients. all the visitors are most welcome to give feedback. Small effort can make big impact...!</subtitle><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://medicamomentosa.blogspot.com/feeds/posts/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7692026254079067189/posts/default?redirect=false'/><link rel='alternate' type='text/html' href='http://medicamomentosa.blogspot.com/'/><link rel='hub' href='http://pubsubhubbub.appspot.com/'/><author><name>Uttam Pachya</name><uri>http://www.blogger.com/profile/15184965553004802347</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='26' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEisqfmaQA4Ryp73WpxtMkvhjeNdnrCAwAIJS9VIQjFQ2K--U7NOkEsDDkNvQI3SPJvRc9iA9yB9h0wGeWxdc09nU4A4XIBwRHm-V27s3JrYnLtVEEfRBLIXu_ZzFf4WCw/s113/*'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>5</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>25</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-7692026254079067189.post-111241326884619910</id><published>2016-03-03T08:13:00.000-08:00</published><updated>2016-03-03T08:13:24.739-08:00</updated><title type='text'>mother’s smile: our satisfaction</title><content type='html'>&lt;div dir=&quot;ltr&quot; style=&quot;text-align: left;&quot; trbidi=&quot;on&quot;&gt;
&lt;!--[if gte mso 9]&gt;&lt;xml&gt;
 &lt;w:WordDocument&gt;
  &lt;w:View&gt;Normal&lt;/w:View&gt;
  &lt;w:Zoom&gt;0&lt;/w:Zoom&gt;
  &lt;w:TrackMoves/&gt;
  &lt;w:TrackFormatting/&gt;
  &lt;w:PunctuationKerning/&gt;
  &lt;w:ValidateAgainstSchemas/&gt;
  &lt;w:SaveIfXMLInvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;
  &lt;w:IgnoreMixedContent&gt;false&lt;/w:IgnoreMixedContent&gt;
  &lt;w:AlwaysShowPlaceholderText&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;
  &lt;w:DoNotPromoteQF/&gt;
  &lt;w:LidThemeOther&gt;EN-US&lt;/w:LidThemeOther&gt;
  &lt;w:LidThemeAsian&gt;X-NONE&lt;/w:LidThemeAsian&gt;
  &lt;w:LidThemeComplexScript&gt;X-NONE&lt;/w:LidThemeComplexScript&gt;
  &lt;w:Compatibility&gt;
   &lt;w:BreakWrappedTables/&gt;
   &lt;w:SnapToGridInCell/&gt;
   &lt;w:WrapTextWithPunct/&gt;
   &lt;w:UseAsianBreakRules/&gt;
   &lt;w:DontGrowAutofit/&gt;
   &lt;w:SplitPgBreakAndParaMark/&gt;
   &lt;w:DontVertAlignCellWithSp/&gt;
   &lt;w:DontBreakConstrainedForcedTables/&gt;
   &lt;w:DontVertAlignInTxbx/&gt;
   &lt;w:Word11KerningPairs/&gt;
   &lt;w:CachedColBalance/&gt;
  &lt;/w:Compatibility&gt;
  &lt;w:BrowserLevel&gt;MicrosoftInternetExplorer4&lt;/w:BrowserLevel&gt;
  &lt;m:mathPr&gt;
   &lt;m:mathFont m:val=&quot;Cambria Math&quot;/&gt;
   &lt;m:brkBin m:val=&quot;before&quot;/&gt;
   &lt;m:brkBinSub m:val=&quot;&amp;#45;-&quot;/&gt;
   &lt;m:smallFrac m:val=&quot;off&quot;/&gt;
   &lt;m:dispDef/&gt;
   &lt;m:lMargin m:val=&quot;0&quot;/&gt;
   &lt;m:rMargin m:val=&quot;0&quot;/&gt;
   &lt;m:defJc m:val=&quot;centerGroup&quot;/&gt;
   &lt;m:wrapIndent m:val=&quot;1440&quot;/&gt;
   &lt;m:intLim m:val=&quot;subSup&quot;/&gt;
   &lt;m:naryLim m:val=&quot;undOvr&quot;/&gt;
  &lt;/m:mathPr&gt;&lt;/w:WordDocument&gt;
&lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;
 &lt;w:WordDocument&gt;
  &lt;w:View&gt;Normal&lt;/w:View&gt;
  &lt;w:Zoom&gt;0&lt;/w:Zoom&gt;
  &lt;w:TrackMoves/&gt;
  &lt;w:TrackFormatting/&gt;
  &lt;w:PunctuationKerning/&gt;
  &lt;w:ValidateAgainstSchemas/&gt;
  &lt;w:SaveIfXMLInvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;
  &lt;w:IgnoreMixedContent&gt;false&lt;/w:IgnoreMixedContent&gt;
  &lt;w:AlwaysShowPlaceholderText&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;
  &lt;w:DoNotPromoteQF/&gt;
  &lt;w:LidThemeOther&gt;EN-US&lt;/w:LidThemeOther&gt;
  &lt;w:LidThemeAsian&gt;X-NONE&lt;/w:LidThemeAsian&gt;
  &lt;w:LidThemeComplexScript&gt;X-NONE&lt;/w:LidThemeComplexScript&gt;
  &lt;w:Compatibility&gt;
   &lt;w:BreakWrappedTables/&gt;
   &lt;w:SnapToGridInCell/&gt;
   &lt;w:WrapTextWithPunct/&gt;
   &lt;w:UseAsianBreakRules/&gt;
   &lt;w:DontGrowAutofit/&gt;
   &lt;w:SplitPgBreakAndParaMark/&gt;
   &lt;w:DontVertAlignCellWithSp/&gt;
   &lt;w:DontBreakConstrainedForcedTables/&gt;
   &lt;w:DontVertAlignInTxbx/&gt;
   &lt;w:Word11KerningPairs/&gt;
   &lt;w:CachedColBalance/&gt;
  &lt;/w:Compatibility&gt;
  &lt;w:BrowserLevel&gt;MicrosoftInternetExplorer4&lt;/w:BrowserLevel&gt;
  &lt;m:mathPr&gt;
   &lt;m:mathFont m:val=&quot;Cambria Math&quot;/&gt;
   &lt;m:brkBin m:val=&quot;before&quot;/&gt;
   &lt;m:brkBinSub m:val=&quot;&amp;#45;-&quot;/&gt;
   &lt;m:smallFrac m:val=&quot;off&quot;/&gt;
   &lt;m:dispDef/&gt;
   &lt;m:lMargin m:val=&quot;0&quot;/&gt;
   &lt;m:rMargin m:val=&quot;0&quot;/&gt;
   &lt;m:defJc m:val=&quot;centerGroup&quot;/&gt;
   &lt;m:wrapIndent m:val=&quot;1440&quot;/&gt;
   &lt;m:intLim m:val=&quot;subSup&quot;/&gt;
   &lt;m:naryLim m:val=&quot;undOvr&quot;/&gt;
  &lt;/m:mathPr&gt;&lt;/w:WordDocument&gt;
&lt;/xml&gt;&lt;![endif]--&gt;

&lt;br /&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class=&quot;separator&quot; style=&quot;clear: both; text-align: center;&quot;&gt;
&lt;a href=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjxiw-iWQ0rWBMpZ3pQx5-32hMfZU1Rw1lOZWKv2qA-6gNVStz6nl36qsrhZU8zthqVI520a8CWM8X4eVpZ7wk4vefzrolzC6kMaTnboZJDql4Jp4NsOHoQfAQPvgGPP18NRt6fNmZqngQc/s1600/12790954_10154592499104606_8606238175232898909_n.jpg&quot; imageanchor=&quot;1&quot; style=&quot;clear: left; float: left; margin-bottom: 1em; margin-right: 1em;&quot;&gt;&lt;img border=&quot;0&quot; height=&quot;240&quot; src=&quot;https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjxiw-iWQ0rWBMpZ3pQx5-32hMfZU1Rw1lOZWKv2qA-6gNVStz6nl36qsrhZU8zthqVI520a8CWM8X4eVpZ7wk4vefzrolzC6kMaTnboZJDql4Jp4NsOHoQfAQPvgGPP18NRt6fNmZqngQc/s320/12790954_10154592499104606_8606238175232898909_n.jpg&quot; width=&quot;320&quot; /&gt;&lt;/a&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
When a mother is asking me for undergoing CS with cry when
she can not bear with her labor pain, It puts me in dilemma and &lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp;&lt;/span&gt;I ask myself what to do next: wait for vaginal
delivery or immediate for CS? &lt;span style=&quot;mso-spacerun: yes;&quot;&gt;&amp;nbsp;&lt;/span&gt;Finally I answer
myself and those mother who asks me to undergo CS : try for vaginal delivery,
if you can not, we are always here to undergo CS. We always encourage to undergo
vaginal delivery rather than surgical intervention.&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
It always strikes my mind what if baby outcome is bad while allowing
vaginal delivery despite their request to go for CS. Still mother’s and baby’s
outcome are not ascertained after going for CS.&amp;nbsp;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
Here is one lady who asked me for CS as she could not bear
the labor pain. Here we can assume how much pain is there in mother despite her
greatest capacity to bear up pain for all miseries and pains. Later, this pain changes
into love that is always there with her heart to care her children. We encouraged
her to go for normal vaginal delivery and she finally did it at midnight. Next
day, in morning round, she thanked me with smile, ‘Thank you doctor for your
encouragement.’&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
her husband was also smiling nearby her. &lt;/div&gt;
&lt;div class=&quot;MsoNormal&quot;&gt;
&lt;br /&gt;&lt;/div&gt;
&lt;!--[if gte mso 9]&gt;&lt;xml&gt;
 &lt;w:LatentStyles DefLockedState=&quot;false&quot; DefUnhideWhenUsed=&quot;true&quot;
  DefSemiHidden=&quot;true&quot; DefQFormat=&quot;false&quot; DefPriority=&quot;99&quot;
  LatentStyleCount=&quot;267&quot;&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;0&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Normal&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;heading 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 7&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 8&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;9&quot; QFormat=&quot;true&quot; Name=&quot;heading 9&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 7&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 8&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; Name=&quot;toc 9&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;35&quot; QFormat=&quot;true&quot; Name=&quot;caption&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;10&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Title&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;1&quot; Name=&quot;Default Paragraph Font&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;11&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtitle&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;22&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Strong&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;20&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Emphasis&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;59&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Table Grid&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; UnhideWhenUsed=&quot;false&quot; Name=&quot;Placeholder Text&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;1&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;No Spacing&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; UnhideWhenUsed=&quot;false&quot; Name=&quot;Revision&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;34&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;List Paragraph&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;29&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Quote&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;30&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Quote&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 1&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 2&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 3&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 4&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 5&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;60&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Shading Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;61&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light List Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;62&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Light Grid Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;63&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 1 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;64&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Shading 2 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;65&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 1 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;66&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium List 2 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;67&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 1 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;68&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 2 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;69&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Medium Grid 3 Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;70&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Dark List Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;71&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Shading Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;72&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful List Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;73&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; Name=&quot;Colorful Grid Accent 6&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;19&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtle Emphasis&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;21&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Emphasis&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;31&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Subtle Reference&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;32&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Intense Reference&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;33&quot; SemiHidden=&quot;false&quot;
   UnhideWhenUsed=&quot;false&quot; QFormat=&quot;true&quot; Name=&quot;Book Title&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;37&quot; Name=&quot;Bibliography&quot;/&gt;
  &lt;w:LsdException Locked=&quot;false&quot; Priority=&quot;39&quot; QFormat=&quot;true&quot; Name=&quot;TOC Heading&quot;/&gt;
 &lt;/w:LatentStyles&gt;
&lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 10]&gt;
&lt;style&gt;
 /* Style Definitions */
 table.MsoNormalTable
 {mso-style-name:&quot;Table Normal&quot;;
 mso-tstyle-rowband-size:0;
 mso-tstyle-colband-size:0;
 mso-style-noshow:yes;
 mso-style-priority:99;
 mso-style-qformat:yes;
 mso-style-parent:&quot;&quot;;
 mso-padding-alt:0in 5.4pt 0in 5.4pt;
 mso-para-margin-top:0in;
 mso-para-margin-right:0in;
 mso-para-margin-bottom:10.0pt;
 mso-para-margin-left:0in;
 line-height:115%;
 mso-pagination:widow-orphan;
 font-size:11.0pt;
 font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;;
 mso-ascii-font-family:Calibri;
 mso-ascii-theme-font:minor-latin;
 mso-fareast-font-family:&quot;Times New Roman&quot;;
 mso-fareast-theme-font:minor-fareast;
 mso-hansi-font-family:Calibri;
 mso-hansi-theme-font:minor-latin;}
&lt;/style&gt;
&lt;![endif]--&gt;&lt;/div&gt;
</content><link rel='replies' type='application/atom+xml' href='http://medicamomentosa.blogspot.com/feeds/111241326884619910/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medicamomentosa.blogspot.com/2016/03/mothers-smile-our-satisfaction.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7692026254079067189/posts/default/111241326884619910'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7692026254079067189/posts/default/111241326884619910'/><link rel='alternate' type='text/html' href='http://medicamomentosa.blogspot.com/2016/03/mothers-smile-our-satisfaction.html' title='mother’s smile: our satisfaction'/><author><name>Uttam Pachya</name><uri>http://www.blogger.com/profile/15184965553004802347</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='26' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEisqfmaQA4Ryp73WpxtMkvhjeNdnrCAwAIJS9VIQjFQ2K--U7NOkEsDDkNvQI3SPJvRc9iA9yB9h0wGeWxdc09nU4A4XIBwRHm-V27s3JrYnLtVEEfRBLIXu_ZzFf4WCw/s113/*'/></author><media:thumbnail xmlns:media="http://search.yahoo.com/mrss/" url="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjxiw-iWQ0rWBMpZ3pQx5-32hMfZU1Rw1lOZWKv2qA-6gNVStz6nl36qsrhZU8zthqVI520a8CWM8X4eVpZ7wk4vefzrolzC6kMaTnboZJDql4Jp4NsOHoQfAQPvgGPP18NRt6fNmZqngQc/s72-c/12790954_10154592499104606_8606238175232898909_n.jpg" height="72" width="72"/><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7692026254079067189.post-8552776792518758179</id><published>2012-02-15T22:08:00.000-08:00</published><updated>2012-02-15T22:08:31.825-08:00</updated><title type='text'>Gene Therapy Meets Stem Cells</title><content type='html'>&lt;div dir=&quot;ltr&quot; style=&quot;text-align: left;&quot; trbidi=&quot;on&quot;&gt;&lt;br /&gt;
&lt;dl class=&quot;articleTabs tabPanel lastChild&quot; style=&quot;font-family: Arial,Helvetica,sans-serif; text-align: justify;&quot;&gt;&lt;dd id=&quot;article&quot; style=&quot;display: block;&quot;&gt;&lt;div class=&quot;section&quot;&gt; &lt;h1&gt;Gene Therapy Meets Stem Cells&lt;/h1&gt;
&lt;div class=&quot;authors&quot; style=&quot;color: #999999;&quot;&gt;Robert A. Sandhaus, M.D., Ph.D.&lt;/div&gt;&lt;div class=&quot;citationLine&quot; style=&quot;color: #999999;&quot;&gt;&lt;span class=&quot;citation&quot;&gt;N Engl J Med 2012;  366:567-569 &lt;/span&gt;&lt;a href=&quot;http://www.nejm.org/toc/nejm/366/6/&quot;&gt;February 9, 2012&lt;/a&gt;&lt;/div&gt;&lt;dl class=&quot;articleTabs tabPanel lastChild&quot;&gt;&lt;dd id=&quot;article&quot; style=&quot;display: block;&quot;&gt;&lt;div class=&quot;section&quot;&gt; 
&lt;/div&gt;&lt;/dd&gt;&lt;/dl&gt;&lt;br /&gt;
&lt;br /&gt;
Stem  cell–based therapies have the potential to repair and even correct the  defects related to human diseases. Although tantalizing niche  applications have moved forward in the clinical setting, progress seems  to be slow, and ethical challenges have yet to be definitively  addressed. The goal of developing pluripotent cells that can transmute  to organ-specific maturity at our direction, and possibly cure many  human diseases, has yet to be attained.&lt;br /&gt;
With recent advances,  however, gene correction involving stem cells is closer to being within  our grasp. Although techniques for correcting genetic abnormalities have  been available in the laboratory for years, the tools for manipulating  the genome tend to leave traces of unwanted genetic material within the  cell or within the genes themselves. Recently, Yusa and colleagues  described a tour-de-force study involving the correction of a single  gene mutation in induced pluripotent stem cells (iPSCs) derived from  patients&#39; own dermal fibroblasts.&lt;span class=&quot;ref&quot;&gt;&lt;a class=&quot;showRefLayer&quot; href=&quot;http://www.nejm.org/doi/full/10.1056/NEJMcibr1113400?query=TOC#ref1&quot; rel=&quot;#refLayer&quot;&gt;1&lt;/a&gt;&lt;/span&gt;  (Since these stem cells are typically derived from a differentiated  somatic cell, they differ from embryonic stem cells, which are derived  from the early embryo.) Using techniques that appear to leave no  residual sequences behind, these investigators replaced a mutated DNA  sequence within patient-derived iPSCs with one encoding the normal gene  product.&lt;br /&gt;
The authors chose to study alpha&lt;sub&gt;1&lt;/sub&gt;-antitrypsin deficiency, which is caused by mutations in &lt;em&gt;SERPINA1,&lt;/em&gt; the gene that encodes this serine protease inhibitor (PI). The “normal” variant of this gene (designated &lt;em&gt;PI*M&lt;/em&gt;) differs from the most common, severely deficient genotype (&lt;em&gt;PI*Z&lt;/em&gt;) by a single base pair, leading to the substitution of a single amino acid (Glu342Lys) in the alpha&lt;sub&gt;1&lt;/sub&gt;-antitrypsin  protein. The corrected iPSCs were stimulated to acquire the  characteristics of hepatocytes, appropriately including the synthesis  and secretion of normal alpha&lt;sub&gt;1&lt;/sub&gt;-antitrypsin. After  intrasplenic injection into mice these iPSC-derived, gene-corrected  hepatocytes were shown to populate the liver of these mice and to  maintain their hepatocyte-like and alpha&lt;sub&gt;1&lt;/sub&gt;-antitrypsin–producing characteristics for many weeks.&lt;br /&gt;
&lt;a class=&quot;figureLink viewType-Layer viewClass-ImageViewerLayer event-articleThumb&quot; href=&quot;http://www.nejm.org/action/showImage?doi=10.1056%2FNEJMcibr1113400&amp;amp;iid=f01&quot; style=&quot;clear: right; float: right; margin-bottom: 1em; margin-left: 1em;&quot;&gt;&lt;img alt=&quot;&quot; src=&quot;http://www.nejm.org/na102/home/ACS/publisher/mms/journals/content/nejm/2012/nejm_2012.366.issue-6/nejmcibr1113400/production/images/small/nejmcibr1113400_f1.gif&quot; /&gt;&lt;/a&gt;Alpha&lt;sub&gt;1&lt;/sub&gt;-antitrypsin  deficiency is only one of many monogenic diseases that could be  potential targets for this type of corrective approach. Yusa and  colleagues go so far as to predict that, should this technology be found  to be safe and effective, iPSCs derived from a person could be returned  — corrected and hepatocyte-like — to that same person in approximately 4  months (&lt;a class=&quot;viewType-Layer viewClass-ImageViewerLayer&quot; href=&quot;http://www.nejm.org/action/showImage?doi=10.1056%2FNEJMcibr1113400&amp;amp;iid=f01&quot;&gt;Figure 1&lt;/a&gt;&lt;span class=&quot;fig&quot;&gt;&lt;span class=&quot;figureTitle&quot;&gt;Figure 1&lt;/span&gt;&lt;span class=&quot;figureCaption&quot;&gt;Ameliorating Alpha&lt;sub&gt;1&lt;/sub&gt;-Antitrypsin Deficiency.&lt;/span&gt;&lt;/span&gt;).  Although it is difficult to achieve the dual goals of safety and  efficacy for any new therapeutic agent, the use of genetically  manipulated iPSCs as a form of therapy poses unique safety issues, some  of which these investigators have addressed. For example, by using  native stem cells (derived from a person&#39;s own somatic cells), these  authors have taken important steps toward addressing concerns about the  possible rejection of or reaction to these iPSC-derived hepatocytes.&lt;br /&gt;
Stem  cells accumulate mutations throughout their genome as they multiply in  culture. Some mutations are predictable and well characterized, whereas  others appear to occur at random. Of concern is the possibility that an  acquired mutation could possess oncogenic properties and lead to  neoplasia. The authors offer two observations relative to these  concerns: They compared the mutations acquired during growth in culture  of both uncorrected iPSCs and gene-corrected iPSCs and found no  important differences between the two. They also observed no cancers in  the mice that had received the modified iPSCs after 2 weeks. Although  these findings are reassuring, they represent only a first step toward  documenting the safety of such procedures.&lt;br /&gt;
Assuming that the  safety of iPSCs will eventually be addressed, we can speculate about the  clinical application of patient-specific iPSC therapy in alpha&lt;sub&gt;1&lt;/sub&gt;-antitrypsin  deficiency as an illustrative example. Liver failure develops during  the first months of life in about 2 to 3% of infants born with this  deficiency. Use of corrected iPSCs to prevent disease in infants would  probably involve intrauterine treatment or embryonic manipulation before  implantation (though it might be easier to select an embryo that lacks  the mutation, if one is available). Since this approach comes close to  what could be considered embryonal stem cells, it would be safer to  focus on instituting treatment later in the life of the affected person.  More insidious liver injury, usually manifesting as cirrhosis, can  occur at any time in persons with alpha&lt;sub&gt;1&lt;/sub&gt;-antitrypsin  deficiency. Destructive lung disease is the other major clinical  manifestation of this disorder. It is well accepted that environmental  factors increase the risks of lung and liver disease in patients with  this disorder and that exposures during childhood are at least as  important as exposures later in life. The “corrected iPSC” approach  might therefore find its best application early in life, thus raising  the stakes in terms of safety, especially with respect to the risk of  neoplasia.&lt;br /&gt;
&lt;/div&gt;&lt;a href=&quot;http://www.nejm.org/doi/suppl/10.1056/NEJMcibr1113400/suppl_file/nejmcibr1113400_disclosures.pdf&quot;&gt;Disclosure forms&lt;/a&gt; provided by the author are available with the full text of this article at NEJM.org.&lt;br /&gt;
&lt;div class=&quot;section&quot;&gt;&lt;div class=&quot;sourceInfo&quot;&gt;&lt;h3&gt;Source Information&lt;/h3&gt;From National Jewish Health, Denver; and AlphaNet, Miami.&lt;/div&gt;&lt;/div&gt;&lt;/dd&gt;&lt;/dl&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://medicamomentosa.blogspot.com/feeds/8552776792518758179/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medicamomentosa.blogspot.com/2012/02/gene-therapy-meets-stem-cells.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7692026254079067189/posts/default/8552776792518758179'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7692026254079067189/posts/default/8552776792518758179'/><link rel='alternate' type='text/html' href='http://medicamomentosa.blogspot.com/2012/02/gene-therapy-meets-stem-cells.html' title='Gene Therapy Meets Stem Cells'/><author><name>Uttam Pachya</name><uri>http://www.blogger.com/profile/15184965553004802347</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='26' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEisqfmaQA4Ryp73WpxtMkvhjeNdnrCAwAIJS9VIQjFQ2K--U7NOkEsDDkNvQI3SPJvRc9iA9yB9h0wGeWxdc09nU4A4XIBwRHm-V27s3JrYnLtVEEfRBLIXu_ZzFf4WCw/s113/*'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7692026254079067189.post-7360380265303461203</id><published>2012-01-31T05:26:00.000-08:00</published><updated>2012-01-31T05:26:23.746-08:00</updated><title type='text'>Polio consultant awarded prestigious Gates Vaccine Innovation Award</title><content type='html'>&lt;div dir=&quot;ltr&quot; style=&quot;text-align: left;&quot; trbidi=&quot;on&quot;&gt;&lt;div class=&quot;itemDate&quot;&gt;&lt;span id=&quot;dnn_ctr1299_ViewItem_lblDate&quot;&gt;Wednesday, January 25, 2012&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;itemTitle&quot;&gt;&lt;span id=&quot;dnn_ctr1299_ViewItem_lblItemTitle&quot;&gt;Polio consultant awarded prestigious Gates Vaccine Innovation Award &lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;itemDesc&quot;&gt;&lt;span id=&quot;dnn_ctr1299_ViewItem_lblItemDesc&quot;&gt;&lt;/span&gt;&lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;&lt;em&gt;The  Bill and Melinda Gates Foundation has awarded its prestigious Vaccine  Innovation Award to polio consultant Dr Asm Amjad Hossain&lt;/em&gt;&lt;/div&gt;&lt;br /&gt;
&lt;div class=&quot;oneItemLeft&quot; id=&quot;dnn_ctr1299_ViewItem_panMainImg&quot; style=&quot;width: 373px;&quot;&gt;            &lt;img alt=&quot;&amp;amp;lt;P align=justify&amp;amp;gt;&amp;amp;lt;EM&amp;amp;gt;The Bill and Melinda Gates Foundation has awarded its prestigious Vaccine Innovation Award to polio consultant Dr Asm Amjad Hossain&amp;amp;lt;/EM&amp;amp;gt;&amp;amp;lt;/P&amp;amp;gt;&quot; class=&quot;imgMain&quot; id=&quot;dnn_ctr1299_ViewItem_imgMain&quot; src=&quot;http://www.polioeradication.org/DesktopModules/Sobot_Items/Handlers/ThumbMediaHandler.ashx?path=/Portals/0/Media/Original/181.jpg&amp;amp;width=480&amp;amp;height=319&amp;amp;resizeType=1&quot; style=&quot;border-width: 0px;&quot; /&gt;         &lt;div class=&quot;SubSubHead&quot;&gt;&lt;span id=&quot;dnn_ctr1299_ViewItem_lblImgDesc&quot;&gt;Melinda  Gates, co-chair of the Bill and Melinda Gates Foundation, meets with Dr  Asm Amjad Hossain, the recipient of the first Gates Vaccine Innovation  Award&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;SubSubHead&quot;&gt;&lt;span id=&quot;dnn_ctr1299_ViewItem_lblImgCredit&quot;&gt;Bill and Melinda Gates Foundation&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;span id=&quot;dnn_ctr1299_ViewItem_lblBody&quot;&gt;&lt;div align=&quot;justify&quot;&gt;Dr  Hossain, originally from Bangladesh and currently based in Nigeria  supporting the country&#39;s polio eradication efforts there, received the  Award from among 117 nominations encompassing a range of innovative  solutions to increase vaccination coverage. &lt;br /&gt;
&lt;br /&gt;
The Award is in  direct recognition of Dr Hossain&#39;s innovative work in raising  immunization coverage rates in key districts of Bangladesh, by  institutionalising processees for registering pregnant women with  expected delivery dates, annual schedules for vaccine sessions, and key  active community outreach strategies. &quot;(These innovations) show how  looking at old problems in new ways can make a profound difference,&quot;  said Mr Bill Gates, co-chair of the Bill and Melinda Gates Foundation.  &quot;Improvements like these are spreading to other locations because of the  commitment and creativity of Dr Hossain and many others like him.&quot; &lt;br /&gt;
&lt;br /&gt;
The  Award was established by the Bill and Melinda Gates Foundation to  recognize and celebrate revolutionary ways in which children in the  poorest parts of the world are immunized. The Award winner is recognized  with US$250,000 and personally acknowledged by Gates Foundation  leadership. &lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;source:&lt;/div&gt;&lt;div align=&quot;justify&quot;&gt; &lt;u&gt;http://www.polioeradication.org/tabid/461/iid/191/Default.aspx&lt;/u&gt;&lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;&lt;br /&gt;
&lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;&lt;br /&gt;
&lt;/div&gt;&lt;/span&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://medicamomentosa.blogspot.com/feeds/7360380265303461203/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medicamomentosa.blogspot.com/2012/01/polio-consultant-awarded-prestigious.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7692026254079067189/posts/default/7360380265303461203'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7692026254079067189/posts/default/7360380265303461203'/><link rel='alternate' type='text/html' href='http://medicamomentosa.blogspot.com/2012/01/polio-consultant-awarded-prestigious.html' title='Polio consultant awarded prestigious Gates Vaccine Innovation Award'/><author><name>Uttam Pachya</name><uri>http://www.blogger.com/profile/15184965553004802347</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='26' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEisqfmaQA4Ryp73WpxtMkvhjeNdnrCAwAIJS9VIQjFQ2K--U7NOkEsDDkNvQI3SPJvRc9iA9yB9h0wGeWxdc09nU4A4XIBwRHm-V27s3JrYnLtVEEfRBLIXu_ZzFf4WCw/s113/*'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7692026254079067189.post-6444656911911608929</id><published>2012-01-08T22:39:00.000-08:00</published><updated>2012-01-08T22:41:22.096-08:00</updated><title type='text'>VIRULENT STRAIN IN THE AIR : TDR TB</title><content type='html'>&lt;div dir=&quot;ltr&quot; style=&quot;text-align: left;&quot; trbidi=&quot;on&quot;&gt;&lt;br /&gt;
&lt;table border=&quot;0&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot;&gt;&lt;tbody&gt;
&lt;tr&gt; &lt;td nowrap=&quot;true&quot;&gt;Publication:  The Times Of India Delhi; &lt;/td&gt; &lt;td nowrap=&quot;true&quot;&gt;Date:  Jan 8, 2012; &lt;/td&gt; &lt;td nowrap=&quot;true&quot;&gt;Section:  Times Nation; &lt;/td&gt; &lt;td nowrap=&quot;true&quot;&gt;Page:  10&lt;/td&gt; &lt;td width=&quot;100%&quot;&gt;&lt;br /&gt;
&lt;/td&gt; &lt;td nowrap=&quot;true&quot;&gt;&lt;br /&gt;
&lt;/td&gt; &lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;&lt;br /&gt;
&lt;span style=&quot;font-family: Arial; font-size: x-large;&quot;&gt;&lt;/span&gt;&amp;nbsp;&lt;span style=&quot;font-family: Arial; font-size: large;&quot;&gt;New, deadlier form of TB hits India &lt;/span&gt;  &lt;span style=&quot;font-family: Arial; font-size: large;&quot;&gt;12 Totally Drug-Resistant Cases Of Killer Disease Isolated At Mumbai Hospital&lt;/span&gt;&lt;br /&gt;
&lt;span style=&quot;font-family: Arial; font-size: large;&quot;&gt; &lt;/span&gt; &lt;b&gt;&lt;span style=&quot;font-family: Arial; font-size: x-small;&quot;&gt;Malathy Iyer TNN &lt;/span&gt;&lt;/b&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;img border=&quot;1&quot; height=&quot;400&quot; id=&quot;Pc0101200&quot; src=&quot;http://epaper.timesofindia.com/Repository/getimage.dll?path=CAP/2012/01/08/10/Img/Pc0101200.jpg&quot; width=&quot;361&quot; /&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;div style=&quot;font-family: Arial,Helvetica,sans-serif;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Mumbai:  Tuberculosis, which kills around 1,000 people every day in India, has  acquired a deadlier edge. A new entity — ominously called Totally  Drug-Resistant TB (TDRTB) — has been isolated in the fluid samples of 12  TB patients in the past three months alone at Hinduja Hospital at Mahim  in Mumbai. The hospital’s laboratory has been certified by the World  Health Organization (WHO) to test TB patients for drug resistance. &lt;br /&gt;
&lt;br /&gt;
&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;While  Iran first reported TDR-TB cases three years ago, India seems to be  only the second country to report this deadly form of the disease.  TDR-TB is the result of the latest mutation of the bacilli after  Multi-Drug-Resistant TB (MDR-TB) and Extremely Drug-Resistant TB  (XDR-TB) were diagnosed earlier. &lt;br /&gt;
&lt;br /&gt;
&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Even more worryingly for  Mumbai, 10 of the 12 TDR-TB cases are from the city, while the other two  are patients from Ratnagiri and Uttar Pradesh. One of the 12 patients  has since died. India sees around 3-4 lakh deaths for all forms of TB  each year, while the world saw 1.7 million deaths in 2009. &lt;br /&gt;
&lt;br /&gt;
&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;As  the full form of TDR-TB suggests, none of the known TB combination  drugs work on the patient. All 12 showed resistance to 12 drugs. “The TB  bacilli have obviously mutated. The emergence of TDR-TB has grave  implications for public health,’’ said Hinduja Hospital’s Dr Zarir  Udwadia, whose observations have been published in the latest issue of  the US-based Clinical Infectious Diseases (CID) peer review journal. His  team started isolating TDR-TB cases among patients with pulmonary TB in  October last year. &lt;br /&gt;
&lt;br /&gt;
&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Dr Amita Athawale, who heads KEM  Hospital’s chest department, said TDR-TB was a reality in India. “The  cases we clinically isolate are just the tip of the iceberg,’’ she said.  TB is one of the biggest killers in India, along with heart attack. &lt;br /&gt;
&lt;br /&gt;
&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Among  tuberculosis patients, drug resistance develops mainly because patients  fail to complete the 6-9 month first treatment phase. “They feel better  within a couple of months of taking the drugs and so they stop taking  them. However, the TB germs in the body are not completely vanquished  and they again multiply,’’ said a senior BMC public health official. &lt;br /&gt;
&lt;br /&gt;
&lt;span style=&quot;font-weight: bold;&quot;&gt;Tuberculosis is one of the most fatal diseases in Mumbai, accounting for nearly 15% (8,953) of the deaths in 2010 &lt;br /&gt;
&lt;/span&gt;&lt;br /&gt;
• Left untreated, each person with active TB can infect 10 to 15 people a year &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
• TB is a contagious disease. Like the common cold, it spreads through the air &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
• Patients resistant to all first-line and second-line drugs are classified as having Totally Drug-Resistant TB (TDR-TB) &lt;br /&gt;
&lt;br /&gt;
An estimated 1.7 million people died from TB worldwide in 2009 &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
• About 3 lakh to 4 lakh die of TB each year in India &lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
• It is believed that more than half the city’s TB patients seek treatment in the private sector &lt;/span&gt;&lt;/div&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://medicamomentosa.blogspot.com/feeds/6444656911911608929/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medicamomentosa.blogspot.com/2012/01/virulent-strain-in-air-tdr-tb.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7692026254079067189/posts/default/6444656911911608929'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7692026254079067189/posts/default/6444656911911608929'/><link rel='alternate' type='text/html' href='http://medicamomentosa.blogspot.com/2012/01/virulent-strain-in-air-tdr-tb.html' title='VIRULENT STRAIN IN THE AIR : TDR TB'/><author><name>Uttam Pachya</name><uri>http://www.blogger.com/profile/15184965553004802347</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='26' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEisqfmaQA4Ryp73WpxtMkvhjeNdnrCAwAIJS9VIQjFQ2K--U7NOkEsDDkNvQI3SPJvRc9iA9yB9h0wGeWxdc09nU4A4XIBwRHm-V27s3JrYnLtVEEfRBLIXu_ZzFf4WCw/s113/*'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-7692026254079067189.post-5616222499945552453</id><published>2012-01-03T01:02:00.000-08:00</published><updated>2012-01-03T01:05:17.530-08:00</updated><title type='text'>clinical pearls: low molecular weight heparin/cushing&#39;s syndrome</title><content type='html'>&lt;div dir=&quot;ltr&quot; style=&quot;text-align: left;&quot; trbidi=&quot;on&quot;&gt;&lt;a href=&quot;http://click2.nejm.org/cts/click?q=66666779%3B67622544%3BbWIuTWUFazv5bDBtN8YCbbLqdMhLDBpc&quot;&gt;LMW heparin/ cushing&#39;s syndrome&lt;/a&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://medicamomentosa.blogspot.com/feeds/5616222499945552453/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://medicamomentosa.blogspot.com/2012/01/clinical-pearls-low-molecular-weight.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/7692026254079067189/posts/default/5616222499945552453'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/7692026254079067189/posts/default/5616222499945552453'/><link rel='alternate' type='text/html' href='http://medicamomentosa.blogspot.com/2012/01/clinical-pearls-low-molecular-weight.html' title='clinical pearls: low molecular weight heparin/cushing&#39;s syndrome'/><author><name>Uttam Pachya</name><uri>http://www.blogger.com/profile/15184965553004802347</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='26' height='32' src='//blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEisqfmaQA4Ryp73WpxtMkvhjeNdnrCAwAIJS9VIQjFQ2K--U7NOkEsDDkNvQI3SPJvRc9iA9yB9h0wGeWxdc09nU4A4XIBwRHm-V27s3JrYnLtVEEfRBLIXu_ZzFf4WCw/s113/*'/></author><thr:total>0</thr:total></entry></feed>